Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96EY9
UPID:
ADAT3_HUMAN
Alternative names:
tRNA-specific adenosine-34 deaminase subunit ADAT3
Alternative UPACC:
Q96EY9
Background:
The Probable inactive tRNA-specific adenosine deaminase-like protein 3, also known as ADAT3, plays a crucial role in the post-transcriptional modification of tRNA. Despite its name suggesting inactivity, ADAT3's involvement in tRNA processing underscores its importance in protein synthesis and cellular function.
Therapeutic significance:
ADAT3 is linked to a neurodevelopmental disorder characterized by developmental delay, intellectual impairment, and dysmorphic facies. Understanding the role of ADAT3 could open doors to potential therapeutic strategies for this disorder.